Prodalim and René Laurent: How Much of 2026 Will Be Real Growth, and How Much Will Be a New Base Year

Where The 2026 Reading Can Go Wrong

The main article argued that Prodalim's shift into higher-value categories is already visible, but not yet fully proved. This follow-up isolates René Laurent because 2026 could look strong even if not much truly changed inside the year itself. The acquisition closed on December 1, 2025, so the annual report captures only one month of actual contribution, while the presentation is already telling the story as if the business had been inside the group for a full year.

Note 26 makes that gap explicit. From the acquisition date through year-end 2025, René Laurent contributed only $532 thousand of revenue and a loss of $241 thousand. In the same note, Prodalim also presents pro forma information as if the acquisition had been completed on January 1, 2025, with consolidated revenue of $355.1 million and net profit of $9.8 million. So before asking whether 2026 will be a good year, the first analytical job is to separate a new base year from genuine economic improvement.

That is only the first layer. The second layer is accounting. Note 26 states that the PPA work had not yet begun when the financial statements were approved, so the recorded amounts, including goodwill, are still provisional and may change materially. Section 22.2 adds that the consideration itself is still subject to post-closing adjustments. So 2026 is not only a test of sales and margin. It is also a test of how much of the current accounting picture is actually final.

How Much Of The Step-Up Is Already Embedded In The Base

The gap between reported 2025 numbers and the pro forma presentation is especially visible inside Specialty Ingredients & Solutions. In the annual report, the segment ended 2025 with $48.9 million of revenue and adjusted EBITDA of $8.0 million. In the presentation, that same activity is already shown on a pro forma basis at $61.0 million of revenue and $10.0 million of EBITDA.

The key point is not only the size of the gap, but its character. The segment EBITDA margin stays at 16.4% both in the reported numbers and in the pro forma presentation. In other words, René Laurent as currently presented is adding scale first. It is not yet being shown as immediate proof of better unit economics.

That distinction matters because it preserves both sides of the story at once. Not all of 2026 will be fake growth. The segment had already grown 36.6% in 2025, and in the fourth quarter the company attributed the group's 6% revenue increase mainly to roughly 50% growth in the unique-ingredients business. So there was already real commercial momentum even before a full-year René Laurent base.

But nearly half of the 2025 pro forma step-up versus 2024 is simply what never made it into the fully reported annual base. So if 2026 delivers healthy segment growth but stays close to the $61 million and 16.4% pro forma profile, most of that will still be a new base year. To call it real growth, investors need to see something above that, either more volume, better margin, or both.

What Is Supposed To Be Real, And Has Not Been Proved Yet

The presentation is not selling only extra revenue. It is selling a broader industrial thesis: cross selling between Prodalim and René Laurent, a new food-flavoring line built on René Laurent knowhow, procurement harmonization across oils, juice concentrates, and colors, logistics and overhead consolidation, and deeper entry into adjacent beverage categories such as syrups, alcoholic beverages, and coffee.

That is exactly where the line sits between a new base year and real growth. A new base year can add revenue without changing the deeper economics of the business very much. Real synergy is supposed to improve something more structural, mix, pricing power, selling leverage, or the cost base.

Based on the materials available through late February 2026, that proof is not yet in the numbers. If those synergies were already showing up, the pro forma presentation would be expected to deliver not only more revenue but also a better EBITDA margin. The fact that the margin remains 16.4% suggests that management is currently asking for analytical credit mainly on scale and category adjacency, not on an immediate rewrite of segment economics.

That is not a criticism of the acquisition itself. The industrial logic is clear. René Laurent sits in beverage flavors in France, and the presentation is trying to show how it can turn the ingredients activity from a fast-growing segment into a broader flavors platform. But precisely because that is the pitch, 2026 has to be judged against a tougher standard than usual. Revenue growth alone will not be enough. The business has to move above the new pro forma base, or show a better margin and better economics per unit sold than what is already embedded in that base.

Why The PPA Can Still Change The Story

If the issue stopped at annualization, that would already be important. But the unfinished PPA adds a second uncertainty layer, and it is not minor. Note 26 lays out only a provisional allocation: $14.0 million of acquired assets, $5.3 million of assumed liabilities, $8.7 million of net identifiable assets, and $10.7 million of goodwill on total purchase cost of $19.35 million.

That chart makes the core point easy to see. More than 55% of the purchase price currently sits in goodwill under a provisional allocation, not under a final map of identifiable assets. Even the lease layer is already inside that provisional map, with $3.233 million of right-of-use assets matched by $3.233 million of lease liabilities. This is not a technical footnote. It is a meaningful part of the balance sheet that is still open to revision.

Precision matters here. An unfinished PPA does not mean the deal is problematic. It does mean that the accounting line for 2026 is still not closed. The reasonable accounting implication, if the final allocation shifts part of the provisional goodwill into identifiable intangible assets or otherwise changes the measurement of the acquired assets and liabilities, is that the amortization profile and below-operating-profit lines could still move. That is not a prediction on direction. It is the analytical consequence of the company stating that the final allocation work has not yet begun.

Section 22.2 reinforces that caution from the legal side as well. It describes consideration of about EUR 15.5 million, subject to cash and debt adjustments at closing and to further checks after completion. In plain terms, both the contractual framework and the accounting framework are saying the same thing: year-end 2025 is the legal closing of the transaction, but not yet the full closing of the picture.

What 2026 Actually Has To Prove

First test: whether Specialty Ingredients moves beyond the pro forma base. If 2026 circles around $61 million of revenue and $10 million of EBITDA, that is mostly full-year consolidation. To argue for real growth, the business needs either a step above those numbers or a better margin.

Second test: whether the synergy story leaves the slide deck and enters the financials. Cross selling, deeper flavors exposure, procurement harmonization, and logistics consolidation have to show up either in a better margin or in growth that is clearly above the new base year.

Third test: how the PPA closes. If the final allocation leaves goodwill as the dominant block, that would suggest that much of the acquired value remains broadly defined at this stage. If more identifiable intangibles are recognized instead, the market will have to update its reading of future reported profit accordingly.

Fourth test: whether René Laurent begins to improve profit quality at group level, not just segment size. Right now, the move from reported Prodalim to pro forma Prodalim lifts revenue much more clearly than it rewrites profitability. 2026 needs to show more than that.

Bottom Line

René Laurent can absolutely help make 2026 a stronger year for Prodalim, but not every visible increase will represent new proof. On the current evidence, the acquisition is changing the scale of the ingredients segment first, and only later may change its economics. At the same time, more than half of the purchase price still sits in provisional goodwill, so the accounting line for 2026 is not fully settled either.

That is why the right read on the coming year has to be more demanding. Not against reported 2025 alone, but against pro forma 2025. Not only against higher revenue, but against the question of whether margins and synergies are actually moving. And not only against the closing of the deal, but against the completion of the PPA. Only if all three begin to line up will it be fair to say that Prodalim gained not just a new base year, but a new growth engine that has actually proved itself.